Читать книгу The SAGE Encyclopedia of Stem Cell Research - Группа авторов - Страница 448

A new national study looking at the safety and effectiveness of new medication developed from adult stem cells for the treatment of ischemic stroke opened at University Hospitals (UH) Case Medical Center. The Phase 2 study will use a cell therapy product called MultiStem. MultiStem is a proprietary medication made from a patented class of early adult stem cells called multipotent adult progenitor cells (MAPCs) that are obtained from the bone marrow. Hundreds of thousands to millions of doses can be made from the bone marrow cells of one donor. The cells do not come from the patient, so they can be made in advance, stored in the hospital, and be used off the shelf.

Unlike conventional drugs, it is believed that MultiStem therapy provides benefit in multiple ways when administered after an acute ischemic stroke. From the preclinical work, MultiStem cells appear to reduce the local inflammatory response and protect neurons in the brain while modulating the body’s general immune response and inflammation, which leads to additional damage to the brain in the days immediately following the stroke. This is an entirely new concept for how cell therapies may provide benefit following CNS injury and holds much potential. Results are anticipated to become known in the coming years.